Cytotoxicity of targeted PLGA nanoparticles: a systematic review

Recent advances in nanotechnology have contributed tremendously to the development and revolutionizing of drug delivery systems in the field of nanomedicine. In particular, targeting nanoparticles based on biodegradable poly(lactic-co-glycolic acid) (PLGA) polymers have gained much interest. However, PLGA nanoparticles remain of concern for their effectiveness against cancer cells and their toxicity to normal cells. The aim of this systematic review is to identify a promising targeting PLGA nanoformulation based on the comparison study of their cytotoxicity potency in different cell lines. A literature search was conducted through the databases of Google Scholar, PubMed, ScienceDirect, Scopus and SpringerLink. The sources studied were published between 2009 and 2019, and a variety of keywords were utilized. In total, 81 manuscripts that met the inclusion and exclusion criteria were selected for analysis based on their cytotoxicity, size, zeta potential, year of publication, type of ligand, active compounds and cell line used. The half maximal inhibitory concentration (IC50) for cytotoxicity was the main measurement in this data extraction, and the SI units were standardized to mu g mL(-1) for a better view of comparison. This systematic review also identified that cytotoxicity potency was inversely proportional to nanoparticle size. The PLGA nanoparticles predominantly exhibited a size of less than 300 nm and absolute zeta potential similar to 20 mV. In conclusion, more comprehensive and critical appraisals of pharmacokinetic, pharmacokinetic, toxicokinetic, in vivo and in vitro tests are required for the investigation of the full value of targeting PLGA nanoparticles for cancer treatment.

Automated summary

Recent advancements in nanotechnology have significantly advanced the development of drug delivery systems in nanomedicine, with a focus on PLGA nanoparticles. However, concerns remain regarding their efficacy against cancer cells and toxicity to normal cells. This systematic review suggests that smaller PLGA nanoparticles exhibit higher cytotoxic potency, with sizes predominantly below 300 nm and zeta potentials around 20 mV. Comprehensive evaluations involving pharmacokinetic, toxicokinetic, in vivo and in vitro tests are needed to fully understand the potential of PLGA nanoparticles for cancer treatment.